VAV3 mediates resistance to breast cancer endocrine therapy
Authors:
- Helena AguilarHAHelena Aguilar
- Ander UrruticoecheaAUAnder Urruticoechea
- Pasi HalonenPHPasi Halonen
- Kazuma KiyotaniKKKazuma Kiyotani
- Taisei MushirodaTMTaisei Mushiroda
- Xavier BarrilXBXavier Barril
- Jordi Serra-MusachJSJordi Serra-Musach
- Abul IslamAIAbul Islam
- Livia CaizziLCLivia Caizzi
- Luciano Di CroceLuciano Di Croce
- Ekaterina NevedomskayaENEkaterina Nevedomskaya
- Wilbert ZwartWZWilbert Zwart
Open Access
- 28 May 2014
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (3) , R53
Abstract
Introduction: Endocrine therapies targeting cell proliferation and survival mediated by estrogen receptor α (ERα) are among the most effective systemic treatments for ERα-positive breast cancer. However, most tumors initially responsive to these therapies acquire resistance through mechanisms that involve ERα transcriptional regulatory plasticity. Herein we identify VAV3 as a critical component in this process. Methods: A cell-based chemical compound screen was carried out to identify therapeutic strategies against resistance to endocrine therapy. Binding to ERα was evaluated by molecular docking analyses, an agonist fluoligand assay and short hairpin (sh)RNA–mediated protein depletion. Microarray analyses were performed to identify altered gene expression. Western blot analysis of signaling and proliferation markers, and shRNA-mediated protein depletion in viability and clonogenic assays, were performed to delineate the role of VAV3. Genetic variation in VAV3 was assessed for association with the response to tamoxifen. Immunohistochemical analyses of VAV3 were carried out to determine its association with therapeutic response and different tumor markers. An analysis of gene expression association with drug sensitivity was carried out to identify a potential therapeutic approach based on differential VAV3 expression. Results: The compound YC-1 was found to comparatively reduce the viability of cell models of acquired resistance. This effect was probably not due to activation of its canonical target (soluble guanylyl cyclase), but instead was likely a result of binding to ERα. VAV3 was selectively reduced upon exposure to YC-1 or ERα depletion, and, accordingly, VAV3 depletion comparatively reduced the viability of cell models of acquired resistance. In the clinical scenario, germline variation in VAV3 was associated with the response to tamoxifen in Japanese breast cancer patients (rs10494071 combined P value = 8.4 × 10−4). The allele association combined with gene expression analyses indicated that low VAV3 expression predicts better clinical outcome. Conversely, high nuclear VAV3 expression in tumor cells was associated with poorer endocrine therapy response. Based on VAV3 expression levels and the response to erlotinib in cancer cell lines, targeting EGFR signaling may be a promising therapeutic strategy. Conclusions: This study proposes VAV3 as a biomarker and a rationale for its use as a signaling target to prevent and/or overcome resistance to endocrine therapy in breast cancer.Keywords
This publication has 66 references indexed in Scilit:
- Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefitBreast Cancer Research and Treatment, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Differential oestrogen receptor binding is associated with clinical outcome in breast cancerNature, 2012
- FOXA1 is a key determinant of estrogen receptor function and endocrine responseNature Genetics, 2010
- Coupling of receptor conformation and ligand orientation determine graded activityNature Chemical Biology, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathwaysInternational Journal of Cancer, 2009
- Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- [9] TM4 Microarray Software Suite2006